

# Thomas Aagaard Rasmussen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/169376/thomas-aagaard-rasmussen-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54  
papers

2,322  
citations

21  
h-index

47  
g-index

60  
ext. papers

2,810  
ext. citations

6.5  
avg, IF

4.82  
L-index

#	Paper	IF	Citations
54	Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. <i>Lancet HIV,the</i> , <b>2014</b> , 1, e13-21	7.8	421
53	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1005142	7.6	352
52	Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. <i>Human Vaccines and Immunotherapeutics</i> , <b>2013</b> , 9, 993-1001	4.4	149
51	Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e463-72	7.8	126
50	Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?. <i>Current Opinion in HIV and AIDS</i> , <b>2016</b> , 11, 394-401	4.2	98
49	Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 1686-1695	11.6	82
48	Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. <i>Molecular Medicine</i> , <b>2011</b> , 17, 466-72	6.2	77
47	Reversal of Latency as Part of a Cure for HIV-1. <i>Trends in Microbiology</i> , <b>2016</b> , 24, 90-97	12.4	73
46	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1005000	7.6	73
45	A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells. <i>Journal of Virology</i> , <b>2016</b> , 90, 4441-4453	6.6	64
44	Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. <i>Journal of Virology</i> , <b>2015</b> , 89, 10176-89	6.6	63
43	Broad activation of latent HIV-1 in vivo. <i>Nature Communications</i> , <b>2016</b> , 7, 12731	17.4	56
42	Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. <i>PLoS ONE</i> , <b>2012</b> , 7, e32445	3.7	49
41	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	45
40	Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , <b>2013</b> , 9, 790-9	4.4	40
39	Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e62074	3.7	39
38	Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. <i>Open Forum Infectious Diseases</i> , <b>2015</b> , 2, ofv037	1	35

37	Between a shock and a hard place: challenges and developments in HIV latency reversal. <i>Current Opinion in Virology</i> , <b>2019</b> , 38, 1-9	7.5	31
36	Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir. <i>Molecular Medicine</i> , <b>2015</b> , 21, 337-45	6.2	30
35	Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. <i>Aids</i> , <b>2017</b> , 31, 771-779	3.5	23
34	Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. <i>Aids</i> , <b>2010</b> , 24, 1315-22	3.5	23
33	Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 328-337	3.1	21
32	Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. <i>BMC Infectious Diseases</i> , <b>2011</b> , 11, 267	4	20
31	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e221-e230	7.8	19
30	Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 3984-94	5.9	18
29	Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. <i>BMJ, The</i> , <b>2012</b> , 345, e5823	5.9	18
28	Ethics of ART interruption after stem-cell transplantation. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e8-10	7.8	17
27	The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients. <i>Aids</i> , <b>2015</b> , 29, 1195-200	3.5	17
26	Cancer therapies in HIV cure research. <i>Current Opinion in HIV and AIDS</i> , <b>2017</b> , 12, 96-104	4.2	16
25	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005740	7.6	16
24	Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	15
23	Patient-reported outcomes in daily clinical practise in HIV outpatient care. <i>International Journal of Infectious Diseases</i> , <b>2018</b> , 69, 108-114	10.5	14
22	HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. <i>Aids</i> , <b>2016</b> , 30, 713-21	3.5	14
21	Clinical Interventions in HIV Cure Research. <i>Advances in Experimental Medicine and Biology</i> , <b>2018</b> , 1075, 285-318	3.6	13
20	In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. <i>Aids</i> , <b>2019</b> , 33, 605-613	3.5	13

19	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	11
18	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Lipopolysaccharide-Induced Inflammatory Responses. <i>MSphere</i> , <b>2018</b> , 3,	5	11
17	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , <b>2021</b> , 65, 103241	8.8	11
16	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e1973-e1981	11.6	11
15	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. <i>Cell Reports</i> , <b>2020</b> , 33, 108502	10.6	10
14	No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , <b>2017</b> , 31, 1137-1141	3.5	9
13	Modeling of Antilateness Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	9
12	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation. <i>Journal of Virus Eradication</i> , <b>2019</b> , 5, 133-137	2.8	8
11	Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 120605	4.3	7
10	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	7
9	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. <i>Aids</i> , <b>2017</b> , 31, 1839-1845	3.5	6
8	Kick and kill for HIV latency. <i>Lancet, The</i> , <b>2020</b> , 395, 844-846	4.0	6
7	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabl3836	17.5	6
6	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , <b>2021</b> , 65, 103252	8.8	5
5	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. <i>Aids</i> , <b>2021</b> , 35, 1631-1636	3.5	2
4	Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound. <i>Aids</i> , <b>2021</b> , 35, 2269-2279	3.5	2
3	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , <b>2022</b> , 36, 75-82	3.5	2
2	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , <b>2021</b> ,	5.3	2

1 Immune checkpoint blockade in HIV.. *EBioMedicine*, **2022**, 76, 103840

8.8 1